<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03705429</url>
  </required_header>
  <id_info>
    <org_study_id>REaCT-Low Risk HER-2</org_study_id>
    <nct_id>NCT03705429</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer</brief_title>
  <official_title>A Multi-Centre Randomized Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will&#xD;
      receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with&#xD;
      trastuzumab [TC-H] or weekly paclitaxel with trastuzumab [P-H]) at the standard approved&#xD;
      doses, aiming to gather more information regarding cost-effectiveness, toxicity, quality of&#xD;
      life (QoL), patient reported outcomes and clinical benefits of the two treatment strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will&#xD;
      receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with&#xD;
      trastuzumab [TC-H] or weekly paclitaxel with trastuzumab [P-H]) at the standard approved&#xD;
      doses. The primary objective is to estimate the feasibility of opening a pragmatic clinical&#xD;
      trial with an Integrated Consent Model Secondary objectives are: Compare adverse events/&#xD;
      toxicity profile between the two different approaches (i.e. neutropenia, peripheral&#xD;
      neuropathy, treatment-related hospitalizations, proportion of patients completing the&#xD;
      chemotherapy component of their treatment); Estimate the cost of each chemotherapy regimen&#xD;
      and potential cost-effectiveness analysis from the perspective of Canada's health care&#xD;
      system; Evaluate the impact on activities of daily living as reflected by self-reported&#xD;
      fatigue and pain using the FACT-Taxane and FACIT-Fatigue scores. In this study, the&#xD;
      investigator will obtain oral consent using the prepared REB approved Consent Script. If the&#xD;
      patient agrees to participate, the physician will dictate in the progress note they have had&#xD;
      the above conversation with the patient. There will be no need for the patient to sign an&#xD;
      informed consent form.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of performing a pragmatic clinical trial with an Integrated Consent Model.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Feasibility of performing this study will be measured with 2 composite endpoints: number of patients who received either TC-H or P-H chemotherapy compared to the number of participants who were approached to enter the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events/ toxicity profile between the two different approaches.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Toxicity profile (NCI CTC version 4.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of each chemotherapy regimen and potential cost-effectiveness analysis.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Health system cost of each chemotherapy regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Cost per one quality-adjusted life year (QALY) gained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Use of primary or secondary febrile neutropenia prophylaxis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as reflected by self-reported fatigue using FACIT-Fatigue scores.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-Fatigue) scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as reflected by self-reported pain using FACT-Taxane scores</measure>
    <time_frame>up to 12 motnhs.</time_frame>
    <description>Functional Assessment of Cancer Therapy-Taxane Scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>TC-H Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel(P) + Trastuzumab(T)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-H x Paclitaxel (P) + Trastuzumab(T)</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Paclitaxel(P) + Trastuzumab(T)</arm_group_label>
    <arm_group_label>TC-H Chemotherapy</arm_group_label>
    <other_name>Docetaxel, Cyclophosphamide and Trastuzumab</other_name>
    <other_name>Paclitaxel and Trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with HER-2 positive early stage breast cancer for whom TC-H or weekly P-H is&#xD;
             being considered.&#xD;
&#xD;
          -  Able to provide verbal consent.&#xD;
&#xD;
          -  Willing to complete study related-questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent or complete questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Fernandes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

